Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia
Background: Deregulated Notch signaling is implicated in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL. Objectives: This phase I clinical trial assessed...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-07-01
|
| Series: | Therapeutic Advances in Drug Safety |
| Online Access: | https://doi.org/10.1177/20420986241311461 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850074829680541696 |
|---|---|
| author | Jean-Marie Michot Zsofia Balogh Jennifer R. Brown Vincent Ribrag Antoine Hollebecque Rastislav Bahleda Cyril Quivoron Samy Ammari Jean-Yves Scoazec Karim A. Benhadji Christophe Massard |
| author_facet | Jean-Marie Michot Zsofia Balogh Jennifer R. Brown Vincent Ribrag Antoine Hollebecque Rastislav Bahleda Cyril Quivoron Samy Ammari Jean-Yves Scoazec Karim A. Benhadji Christophe Massard |
| author_sort | Jean-Marie Michot |
| collection | DOAJ |
| description | Background: Deregulated Notch signaling is implicated in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL. Objectives: This phase I clinical trial assessed the safety and efficacy of crenigacestat in patients with relapsed or refractory NHL and CLL. The main objectives were to characterize the safety profile, to confirm the recommended phase II dose of crenigacestat in patients with hematological malignancies, and to assess preliminary antitumor activity. Design: A phase I trial enrolling patients with relapsed or refractory NHL and CLL, with Notch tumor alteration based on molecular or immunohistochemistry tumor pre-screening. Methods: Eligible patients received crenigacestat 50 mg orally three times per week, for a 28-day cycle, until disease progression or unacceptable toxicity. Tumor responses were assessed using the Revised Response Criteria for Malignant Lymphoma and the National Cancer Institute Working Group for CLL. Results: Overall, 62 patients (40 with NHL and 22 with CLL) were pre-screened for a Notch alteration. Notch alteration was identified in 21/62 (34%) of patients pre-screened. Nine patients (five with peripheral T-cell NHL and three with CLL) with Notch alteration were eligible for the clinical trial and treated. The most common adverse events in all grades of severity were diarrhea (56%), nausea (56%), platelet count decrease (44%), and fatigue (33%). One patient (11%) with peripheral T-cell lymphoma obtained a partial response. Conclusion: Crenigacestat demonstrated a modest clinical activity at the recommended dose in adult patients with relapsed or refractory NHL or CLL. Trial registration: NCT01695005. |
| format | Article |
| id | doaj-art-8f51cb534e03466397108b5702673b8b |
| institution | DOAJ |
| issn | 2042-0994 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Drug Safety |
| spelling | doaj-art-8f51cb534e03466397108b5702673b8b2025-08-20T02:46:28ZengSAGE PublishingTherapeutic Advances in Drug Safety2042-09942025-07-011610.1177/20420986241311461Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemiaJean-Marie MichotZsofia BaloghJennifer R. BrownVincent RibragAntoine HollebecqueRastislav BahledaCyril QuivoronSamy AmmariJean-Yves ScoazecKarim A. BenhadjiChristophe MassardBackground: Deregulated Notch signaling is implicated in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Crenigacestat (LY3039478) prevents cleavage of Notch proteins and may benefit patients with relapsed or refractory NHL or CLL. Objectives: This phase I clinical trial assessed the safety and efficacy of crenigacestat in patients with relapsed or refractory NHL and CLL. The main objectives were to characterize the safety profile, to confirm the recommended phase II dose of crenigacestat in patients with hematological malignancies, and to assess preliminary antitumor activity. Design: A phase I trial enrolling patients with relapsed or refractory NHL and CLL, with Notch tumor alteration based on molecular or immunohistochemistry tumor pre-screening. Methods: Eligible patients received crenigacestat 50 mg orally three times per week, for a 28-day cycle, until disease progression or unacceptable toxicity. Tumor responses were assessed using the Revised Response Criteria for Malignant Lymphoma and the National Cancer Institute Working Group for CLL. Results: Overall, 62 patients (40 with NHL and 22 with CLL) were pre-screened for a Notch alteration. Notch alteration was identified in 21/62 (34%) of patients pre-screened. Nine patients (five with peripheral T-cell NHL and three with CLL) with Notch alteration were eligible for the clinical trial and treated. The most common adverse events in all grades of severity were diarrhea (56%), nausea (56%), platelet count decrease (44%), and fatigue (33%). One patient (11%) with peripheral T-cell lymphoma obtained a partial response. Conclusion: Crenigacestat demonstrated a modest clinical activity at the recommended dose in adult patients with relapsed or refractory NHL or CLL. Trial registration: NCT01695005.https://doi.org/10.1177/20420986241311461 |
| spellingShingle | Jean-Marie Michot Zsofia Balogh Jennifer R. Brown Vincent Ribrag Antoine Hollebecque Rastislav Bahleda Cyril Quivoron Samy Ammari Jean-Yves Scoazec Karim A. Benhadji Christophe Massard Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia Therapeutic Advances in Drug Safety |
| title | Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia |
| title_full | Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia |
| title_fullStr | Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia |
| title_full_unstemmed | Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia |
| title_short | Notch pathway inhibition with crenigacestat (LY3039478) in a phase I first-in-human clinical trial for patients with relapsed or refractory non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia |
| title_sort | notch pathway inhibition with crenigacestat ly3039478 in a phase i first in human clinical trial for patients with relapsed or refractory non hodgkin lymphoma and b cell chronic lymphocytic leukemia |
| url | https://doi.org/10.1177/20420986241311461 |
| work_keys_str_mv | AT jeanmariemichot notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT zsofiabalogh notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT jenniferrbrown notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT vincentribrag notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT antoinehollebecque notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT rastislavbahleda notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT cyrilquivoron notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT samyammari notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT jeanyvesscoazec notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT karimabenhadji notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia AT christophemassard notchpathwayinhibitionwithcrenigacestatly3039478inaphaseifirstinhumanclinicaltrialforpatientswithrelapsedorrefractorynonhodgkinlymphomaandbcellchroniclymphocyticleukemia |